H. Kreipe

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 172 citations

Medicine, Oncology, Pharmacology +17

A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes

Michael Stadler, Ulrich Germing, Kliche Ko et al. · Leukemia · 2004 · 138 citations

Life Sciences, Immunology, Clinical Immunology +10

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

M. Martín, S.R. Stecklein, Oleg Gluz et al. · Annals of Oncology · 2024 · 27 citations · Full text

Medicine, Bioinformatics, Oncology +16

S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.

Oleg Gluz, H. Kreipe, Tom Degenhardt et al. · Cancer Research · 2011 · 14 citations

Medicine, Oncology, Breast Oncology +16